Bregua Corp 4
4 · Janux Therapeutics, Inc. · Filed Jun 16, 2021
Insider Transaction Report
Form 4
Bregua Corp
10% Owner
Transactions
- Conversion
Series A Convertible Preferred Stock
2021-06-15−526,316→ 0 total→ Common Stock (674,211 underlying) - Conversion
Common Stock
2021-06-15+1,138,665→ 1,138,665 total - Conversion
Common Stock
2021-06-15+247,123→ 3,690,427 total - Conversion
Common Stock
2021-06-15+674,211→ 3,443,304 total - Conversion
Series B Convertible Preferred Stock
2021-06-15−192,914→ 0 total→ Common Stock (247,123 underlying) - Conversion
Common Stock
2021-06-15+1,630,428→ 2,769,093 total - Purchase
Common Stock
2021-06-15$17.00/sh+58,823$999,991→ 3,749,250 total - Conversion
Series Seed Convertible Preferred Stock
2021-06-15−888,888→ 0 total→ Common Stock (1,138,665 underlying) - Conversion
Series Seed 2 Convertible Preferred Stock
2021-06-15−1,272,778→ 0 total→ Common Stock (1,630,428 underlying)
Footnotes (3)
- [F1]Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- [F2]These securities are held directly by Bregua Corporation (Bregua). Klaus Dorner is the Director of Bregua and may be deemed to have voting and investment power with respect to the shares held by Bregua and as a result may be deemed to have beneficial ownership of such shares. Mr. Dorner disclaims beneficial ownership of all shares held by Bregua, except to the extent of his actual pecuniary interest therein, if any.
- [F3]The shares were purchased in the Issuer's initial public offering.